Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins

Background and Rationale：Varicose veins of the lower extremities are a common vascular disorder, affecting approximately 30% of the adult population globally. In China, the number of patients with varicose veins exceeds 120 million, with a higher prevalence in females (66.7%) and a trend towards younger age groups. Traditional treatment methods, such as saphenofemoral ligation and vein stripping, as well as sclerotherapy, are associated with significant trauma and a higher risk of complications, including nerve damage and thrombosis formation. In contrast, radiofrequency ablation (RFA) has emerged as a minimally invasive, effective, and safe treatment option, with a faster recovery time and fewer complications. RFA is now recommended as a first-line treatment in international guidelines.

Despite the advantages of RFA, its adoption in China remains low, with a penetration rate of less than 5%, compared to over 30% in European and American countries. The primary barriers to wider adoption include the high cost of imported equipment (with brands like Medtronic dominating over 90% of the market) and insufficient technical dissemination in grassroots hospitals. In 2022, Xianruida's venous endovenous radiofrequency ablation system was approved for market, marking the first domestic radiofrequency catheter system with independent intellectual property rights. This system features advanced technologies such as an adaptive PID temperature control algorithm, dual-system monitoring, and optimized heating curves, enabling faster heating times (20% shorter than imported devices) and more stable temperature control (fluctuation range of ±1℃), thereby reducing the risk of thermal injury.

Study Objective：The primary objective of this study is to systematically compare the clinical efficacy, safety, and cost-effectiveness of domestic Xianruida radiofrequency catheters and imported Medtronic catheters in the treatment of varicose veins using a single-center, prospective, non-inferiority randomized controlled trial (RCT). Specifically, we aim to verify whether the domestic catheter is non-inferior to the imported product in terms of therapeutic effect and whether it offers significant economic advantages. This will provide comprehensive and scientific evidence for clinical decision-making, optimize treatment strategies for varicose veins, enhance the utilization efficiency of medical resources, and improve patient outcomes.

Study Design and Methodology This study is designed as a single-center, prospective, non-inferiority, randomized controlled trial（RCT）, following the CONSORT statement. The non-inferiority margin for the primary endpoint (venous closure rate at 12 months postoperatively) is set at Δ≤10%, based on international guidelines and similar studies.

Sample Size and Calculation: The sample size is estimated based on the literature and clinical practice. Assuming a postoperative venous closure rate of 95% in the control group (Medtronic catheter), and expecting similar closure rates in the experimental group (Xianruida catheter), with a non-inferiority margin of 10%, a significance level (α) of 0.05 (two-sided), and a power (1-β) of 0.8, the required sample size is 92 patients per group. Considering a 20% dropout rate, a total of 200 patients (100 in each group) will be recruited.

Randomization and Blinding: Patients will be randomly assigned to either the experimental group (Xianruida catheter) or the control group (Medtronic catheter) using a computer-generated block random sequence (block size=4) with central randomization by an independent third party. The study will employ assessor-blinding (ultrasound physicians and follow-up nurses) and patient-blinding. Due to the nature of the procedure and differences in catheter appearance, surgeons will not be blinded, but standardized surgical procedures and training will minimize bias.

Intervention and Postoperative Management： Surgical Procedure: Both groups will undergo standardized RFA (great saphenous vein/small saphenous vein closure) performed by the same surgical team. Catheter parameters will be set according to the manufacturer's instructions (temperature 120℃, withdrawal speed 1cm/min).

Postoperative Management: All patients will receive uniform compression dressing (elastic bandage + Class II compression stockings), oral anticoagulant medication, and painkillers as needed based on the patient's condition.

Outcome Measures Primary Endpoint: Venous closure rate confirmed by ultrasound at 12 months postoperatively (complete closure: no blood flow signal; partial closure: blood flow signal \<10cm).

Secondary Endpoints:

Clinical Effectiveness: VCSS score (venous clinical severity score), AVVQ score (venous disease quality of life score), and CIVIQ-20 quality of life scale at 3, 6, and 12 months postoperatively.

Safety: Intraoperative complications (vascular perforation, catheter failure), postoperative complications (pain VAS score, DVT, skin burns, swelling, numbness, and skin sensation abnormalities), and use of anticoagulant and pain medications.

Cost-Effectiveness: Direct medical costs (catheter cost + surgical consumables + hospitalization costs) and indirect social costs (time to resume normal life).

• Change in Aberdeen Varicose Vein Questionnaire (AVVQ) Score from [Срок оценки: 3, 6, and 12 months]
• Change in Venous Clinical Severity Score (VCSS) from Baseline [Срок оценки: 3, 6, and 12 months]
• Change in CIVIQ-20 Score from Baseline [Срок оценки: 3, 6, and 12 months]
• Number of Intraoperative Complications [Срок оценки: During surgery]
• Number of Postoperative Complications within 30 Days [Срок оценки: 12 months]
• VAS Pain Score on Postoperative Days 1, 3, and 7 [Срок оценки: Days 1, 3, and 7 post-operation]
• Number of Days of Painkiller Use [Срок оценки: Within 30 days post-operation]
• Total Direct Medical Costs per Patient [Срок оценки: 12 months]
• Number of Days to Return to Normal Life [Срок оценки: Within 12 months]